Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints-Reference-Cited by-同舟云学术

Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints

Published:2013-12-20 Issue:12 Volume:8 Page:e82059
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Friedman Ran

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference70 articles.

1. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec ®, Gleevec™);M Henkes;Ther Clin Risk Manag,2008

2. Targeting cancer with small molecule kinase inhibitors;J Zhang;Nat Rev Cancer,2009

3. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain;W Pao;PLoS Med,2005

4. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors;YL Choi;N Engl J Med,2010

5. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors;PA Jänne;Nat Rev Drug Discov,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Singleton mutations in large-scale cancer genome studies: uncovering the tail of cancer genome;NAR Cancer;2024-01-09

2. In silico resources help combat cancer drug resistance mediated by target mutations;Drug Discovery Today;2023-09

3. A mutation-induced drug resistance database (MdrDB);Communications Chemistry;2023-06-14

4. MdrDB: Mutation-induced drug resistance DataBase;2022-10-24

5. Evaluation of residue variability in a conformation‐specific context and during evolutionary sequence reconstruction narrows drug resistance selection in Abl1 tyrosine kinase;Protein Science;2022-06-16